Genetically modified muscle cells which express neurotrophic factors

Patent metadata

Field	Value
Publication number	US-9365828-B2
Application number	US-201214002782-A
Country	US
Kind code	B2
Filing date	Mar 1, 2012
Priority date	Mar 3, 2011
Publication date	Jun 14, 2016
Grant date	Jun 14, 2016

Abstract

An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.

First claim

What is claimed is:

1. A method of treating Amyotrophic Lateral Sclerosis (ALS), comprising intramuscularly administering to a subject in need thereof a therapeutically effective amount of the isolated cell population which comprises at least four subpopulations of muscle progenitor cells, each of the at least four subpopulations being distinct in that they are genetically modified to express a different neurotrophic factor, wherein the neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF), thereby treating ALS.

2. A method of treating peripheral nerve damage, comprising administering to a subject in need thereof at the site of the damage, a therapeutically effective amount of the isolated cell population which comprises at least four subpopulations of muscle progenitor cells, each of the at least four subpopulations being distinct in that they are genetically modified to express a different neurotrophic factor, wherein the neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF), thereby treating the peripheral nerve damage.

Assignees

• Offen Daniel
• Dadon-Nachum Michal
• Ben-Zur Tali
• Melamed Eldad
• Yaffe David
• Univ Ramot
• Yeda Res & Dev

Inventors

• Offen Daniel
• Dadon-Nachum Michal
• Ben-Zur Tali
• Melamed Eldad
• Yaffe David

Classifications

• C12N2501/13

  Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N5/0659

  Satellite cells · CPC title

• A61K38/30

  Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)} · CPC title

• C12N2501/165

  Vascular endothelial growth factor [VEGF] · CPC title